Nanjing-based maker of heparin API and injectable anticoagulants, a major Chinese exporter of generic injectable drugs.
Nanjing-based maker of heparin API and injectable anticoagulants, a major Chinese exporter of generic injectable drugs.
Starts from porcine heparin raw material and moves up the chain, selling the active ingredient (API) to other drugmakers and finished enoxaparin injections to generic-drug marketers abroad. Selling the finished injection earns more per unit than the ingredient.
In one line: A heparin-focused Fresenius Kabi.
Moat: narrow (scale, regulatory licence). Vertically integrated from porcine heparin API to FDA-approved finished injectables, hard to replicate quickly.
Headquarters: Nanjing, China · Employees: 1,558
Size Nanjing King-friend Biochemical Pharmaceutical (603707.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.03B, the 1153rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.47 on 18 Nov 2026.
Performance Over six months the shares fell 2.6%, against -5.1% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 8.7% over the last twelve months (peer median +10.7%); the operating margin is 13.7% (peer median 21.5%).
Valuation It trades at 25.9× forward earnings against a peer median of 18.1× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.6 points above its cost of capital (6.8% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.07B | CN¥3.97B | CN¥3.91B | CN¥3.88B | CN¥3.69B |
| Revenue growth | — | +2% | +1% | +5% | — |
| Gross profit | CN¥1.58B | CN¥1.46B | CN¥1.60B | CN¥1.77B | CN¥1.84B |
| EBITDA | n/a | CN¥971M | CN¥1.15B | -CN¥178M | CN¥1.16B |
| Net income | CN¥425M | CN¥582M | CN¥826M | -CN¥189M | CN¥1.09B |
| Free cash flow | CN¥1.00B | CN¥651M | CN¥1.05B | CN¥1.21B | CN¥159M |
| Capital expenditure | CN¥466M | CN¥560M | CN¥507M | CN¥419M | CN¥470M |
| Total debt | CN¥2.34B | CN¥2.35B | CN¥2.08B | CN¥2.63B | CN¥3.01B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% |
| Sandoz SDZ.SW | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% |
| Pfizer PFE | $160B | +9% | +1% | 26% | 9.9× | -4.3% |
| Sanofi SAN.PA | $114B | +13% | +15% | 27% | 9.7× | -4.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603707.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.7% | -1.0% | 8th highest of 21 |
| 6-month return | -2.6% | -5.1% | 11th highest of 21 |
| Distance from 52-week high | -19.0% | -28.3% | 7th highest of 21 |
| Revenue growth (TTM) | +8.7% | +10.7% | 10th lowest of 20 |
| Operating margin | 13.7% | 21.5% | 6th lowest of 19 |
| Forward P/E | 25.9× | 18.1× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 5.1% | 1.5% | 6th most demanding of 15 |
| Growth delivered (Del g) | +6.4% | +12.3% | 6th lowest of 15 |
| Hurdle (Req g minus delivered) | -1.3 pp | -10.3 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +1.6 pp | +1.3 pp | 10th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.03B | -3% | +9% | 14% | 25.9× | 5.1% | +6.4% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.03B | +19% | -1% | 14% | 16.9× | 1.7% | +15.7% |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.02B | -45% | 0% | -47% | n/a | n/a | n/a |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.04B | +9% | +5% | 22% | 15.9× | -4.7% | +10.6% |
| Hanall Biopharma 009420.KS | South Korea | $2.01B | +12% | +5% | 3% | n/a | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.01B | -10% | +146% | 35% | 32.2× | -2.0% | +341.1% |
| Eris Lifesciences ERIS.NS | India | $1.98B | 0% | +11% | 26% | 27.9× | 26.3% | +20.9% |
| Haw Par H02.SI | Singapore | $2.08B | -25% | -13% | 30% | 11.9× | 3.2% | +15.7% |
| PharmaResearch 214450.KS | South Korea | $2.10B | -24% | +29% | 37% | 15.4× | -11.0% | +37.6% |
| Biohaven BHVN | United States | $1.95B | +46% | n/a | n/a | n/a | n/a | n/a |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.95B | -14% | +11% | 6% | 44.6× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.94B | +6% | +20% | 22% | 8.6× | -10.5% | +40.3% |
| Jinyu Bio-Technology 600201.SS | China | $1.93B | -21% | +22% | 10% | 59.0× | 23.4% | -2.5% |
| Tsumura & 4540.T | Japan | $1.93B | +6% | +13% | 18% | 10.4× | n/a | n/a |
| Grand Pharmaceutical 0512.HK | Hong Kong | $1.93B | -25% | +7% | 13% | 9.4× | 1.2% | +14.1% |
| Shilpa Medicare SHILPAMED.NS | India | $1.91B | +94% | +37% | 21% | 54.3× | n/a | n/a |
| Alivus Life Sciences ALIVUS.NS | India | $1.90B | +36% | +8% | 31% | 23.8× | 20.1% | +6.2% |
| Pfizer PFIZER.NS | India | $1.88B | -20% | +12% | 34% | 21.9× | 11.2% | +2.4% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $1.88B | -12% | -9% | 30% | 18.1× | 8.0% | +9.3% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.19B | +14% | -7% | 15% | 15.0× | -9.7% | -1.5% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.19B | -12% | +18% | n/a | 25.4× | 0.9% | +0.3% |